Cancer immunoediting from immune surveillance to immune escape

Immunology

Volumn 121, Issue 1, 2007, Pages 1-14

  Kim, Ryungsa ^a   Emi, Manabu ^a   Tanabe, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cancer; Immune escape; Immune surveillance; Immunoediting

Indexed keywords

FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; PERFORIN; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANTIGEN SPECIFICITY; CANCER IMMUNOLOGY; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL TRANSFORMATION; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPHOCYTE; METASTASIS; MOLECULAR INTERACTION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HUMANS; IMMUNOLOGIC SURVEILLANCE; NEOPLASMS; TUMOR ESCAPE;

EID: 34047220868     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02587.x     Document Type: Review

References (126)

1. Ehrlich P. Ueber den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 1909; 5:73-290.
2. Burnet FM. Cancer a biological approach. Br Med J 1957; 1:841-7.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8.
4. Dunn GP, Bruce AT, Sheehan KC et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6:722-9.
5. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66:5527-36.
6. Klein G. Immune surveillance - a powerful mechanism with a limited range. Natl Cancer Inst Monogr 1976; 44:109-13.
7. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18:769-78.
8. Old LJ, Boyse EA. Immunology of experimental tumors. Annu Rev Med 1964; 15:167-86.
9. Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971; 7:3-25.
10. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55:329-33.
11. Rygaard J, Povlsen CO. The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. Acta Pathol Microbiol Scand Microbiol Immunol 1974; 82:99-106.
12. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974; 183:534-6.
13. Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA. Functional T cells in athymic nude mice. Proc Natl Acad Sci USA 1984; 81:886-8.
14. Maleckar JR, Sherman LA. The composition of the T cell receptor repertoire in nude mice. J Immunol 1987; 138:3873-6.
15. Engel AM, Svane IM, Mouritsen S, Rygaard J, Clausen J, Werdelin O. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS 1996; 104:629-39.
16. Engel AM, Svane IM, Rygaard J, Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 1997; 45:463-70.
17. Herberman RB, Holden HT. Natural cell-mediated immunity. Adv Cancer Res 1978; 27:305-77.
18. Smyth MJ, Thia KY, Street SE et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191:661-8.
19. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001; 13:459-63.
20. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 2003; 100:9464-9.
21. Girardi M, Oppenheim DE, Steele CR et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294:605-9.
22. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1:447-56.
23. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95:7556-61.
24. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97:192-7.
25. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196:129-34.
26. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20:323-70.
27. van den Broek ME, Kagi D, Ossendorp F et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996; 184:1781-90.
28. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000; 192:755-60.
29. Shinkai Y, Rathbun G, Lam KP et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate VDJ rearrangement. Cell 1992; 68:855-67.
30. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11.
31. Gresser I, Bandu MT, Brouty-Boye D. Interferon and cell division. IX. Interferon-resistant L1210 cells. characteristics and origin. J Natl Cancer Inst 1974; 52:553-9.
32. Affabris E, Romeo G, Federico M, Coccia E, Locardi C, Belardelli F, Rossi GB. Molecular mechanisms of action of interferons in the Friend virus-induced leukemia cell system. Haematologica 1987; 72:76-8.
33. Gresser I, Maury C, Vignaux F, Haller O, Belardelli F, Tovey MG. Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice. J Exp Med 1988; 168:1271-91.
34. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12:677-86.
35. Asselin-Paturel C, Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 2005; 202:461-5.
36. Hoshino K, Kaisho T, Iwabe T, Takeuchi O, Akira S. Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation. Int Immunol 2002; 14:1225-31.
37. Sato K, Hida S, Takayanagi H et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001; 31:3138-46.
38. Hiroishi K, Tuting T, Lotze MT. IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol 2000; 164:567-72.
39. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8:591-9.
40. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-4.
41. Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Moller P. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma. Clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005; 54:661-5.
42. Yasunaga M, Tabira Y, Nakano K, Iida S, Ichimaru N, Nagamoto N, Sakaguchi T. Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma. Ann Thorac Surg 2000; 70:1634-40.
43. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998; 58:5344-7.
44. Yoshimoto M, Sakamoto G, Ohashi Y. Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 1993; 72:2993-3001.
45. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102:18538-43.
46. Haanen JB, Baars A, Gomez R et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006; 55:451-8.
47. Ishigami S, Natsugoe S, Tokuda K et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88:577-83.
48. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg 2003; 20:445-51.
49. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, Zuil M, Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35:23-8.
50. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries 1964-86. Int J Cancer 1995; 60:183-9.
51. Pham SM, Kormos RL, Landreneau RJ, Kawai A, Gonzalez-Cancel I, Hardesty RL, Hattler BG, Griffith BP. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 1995; 60:1623-6.
52. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15:1582-8.
53. Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002; 74:358-62.
54. Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis 2002; 39:E5.
55. Meek DW. The p53 response to DNA damage. DNA Repair (Amst) 2004; 3:1049-56.
56. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005; 331:834-42.
57. Iwakuma T, Lozano G, Flores ER. Li-Fraumeni syndrome: a p53 family affair. Cell Cycle 2005; 4:865-7.
58. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.
59. Klein G, Klein E. Surveillance against tumors - is it mainly immunological? Immunol Lett 2005; 100:29-33.
60. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 2006; 55:1159-84.
61. Mori S, Jewett A, Murakami-Mori K, Cavalcanti M, Bonavida B. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother 1997; 44:282-90.
62. Takeda K, Hayakawa Y, Smyth MJ et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7:94-100.
63. Zitvogel L, Terme M, Borg C, Trinchieri G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr Top Microbiol Immunol 2006; 298:157-74.
64. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991-1045.
65. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2:293-9.
66. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1:41-9.
67. Street SE, Hayakawa Y, Zhan Y et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 2004; 199:879-84.
68. Gollob JA, Sciambi CJ, Huang Z, Dressman HK. Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. Cancer Res 2005; 65:8869-77.
69. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63:4095-100.
70. Wall L, Burke F, Barton C, Smyth J, Balkwill F. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 2003; 9:2487-96.
71. Angiolillo AL, Sgadari C, Taub DD et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182:155-62.
72. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immuno-editing. Cytokine Growth Factor Rev 2002; 13:95-109.
73. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity. A balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005; 54:1137-42.
74. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425:516-21.
75. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164:558-61.
76. Bandholtz L, Guo Y, Palmberg C et al. Hsp90 binds CpG oligonucleotides directly: implications for hsp90 as a missing link in CpG signaling and recognition. Cell Mol Life Sci 2003; 60:422-9.
77. Powell JD, Horton MR. Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res 2005; 31:207-18.
78. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-6.
79. Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 2005; 4:924-33.
80. Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996; 26:1844-50.
81. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immuno-editing. Annu Rev Immunol 2004; 22:329-60.
82. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003; 348:567-8.
83. Cankovic M, Linden MD, Zarbo RJ. Use of microsatellite analysis in detection of tumor lineage as a cause of death in a liver transplant patient. Arch Pathol Laboratory Med 2006; 130:529-32.
84. Morath C, Rohmeiss P, Schwenger V et al. Transmission of donor-derived small-cell carcinoma cells by a nontumor-bearing allograft. Transplantation 2005; 80:540-2.
85. Detry O, De Roover A, de Leval L, Herens C, Delwaide J, Honore P, Meurisse M. Transmission of an undiagnosed sarcoma to recipients of kidney and liver grafts procured in a non-heart beating donor. Liver Transpl 2005; 11:696-9.
86. von Bernstorff W, Voss M, Freichel S et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001; 7:925s-32s.
87. Schmielau J, Nalesnik MA, Finn OJ. Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001; 7:933s-9s.
88. Staibano S, Mascolo M, Tranfa F et al. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int J Immunopathol Pharmacol 2006; 19:171-9.
89. Riccobon A, Gunelli R, Ridolfi R et al. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest 2004; 22:871-7.
90. Lockhart DC, Chan AK, Mak S et al. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001; 129:749-56.
91. Agrawal S, Marquet J, Delfau-Larue MH, Copie-Bergman C, Jouault H, Reyes F, Bensussan A, Farcet JP. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest 1998; 102:1715-23.
92. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 1999; 59:1422-7.
93. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 2000; 95:2015-23.
94. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005; 11:1010-20.
95. Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150-66.
96. Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer - different stories with the same message. Semin Cancer Biol 2003; 13:337-42.
97. Beck C, Schreiber H, Rowley D. Role of TGF-beta in immune-evasion of cancer. Microsc Res Tech 2001; 52:387-95.
98. cHe X, Stuart JM. Prostaglandin E2 selectively inhibits human CD4+ T cells secreting low amounts of both IL-2 and IL-4. J Immunol 1999; 163:6173-9.
99. Erdogan B, Uzaslan E, Budak F et al. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients. Tuberk Toraks 2005; 53:127-31.
100. Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004; 100:2281-91.
101. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006; 55:1584-9.
102. Bellamy WT, Richter L, Sirjani D et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97:1427-34.
103. Munn DH, Sharma MD, Lee JR et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297:1867-70.
104. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 2005; 65:11743-51.
105. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160:1224-32.
106. Xu Q, Briggs J, Park S et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005; 24:5552-60.
107. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54.
108. Kortylewski M, Kujawski M, Wang T et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11:1314-21.
109. Suzuki M, Iizasa T, Ko E et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002; 35:29-34.
110. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003; 97:2767-75.
111. Webb SD, Sherratt JA, Fish RG. Cells behaving badly. A theoretical model for the Fas/FasL system in tumour immunology. Math Biosci 2002; 179:113-29.
112. Doubrovina ES, Doubrovin MM, Vider E et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 2003; 171:6891-9.
113. Huber V, Fais S, Iero M et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005; 128:1796-804.
114. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001; 85:1047-54.
115. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-8.
116. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15.
117. Malmberg KJ. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 2004; 53:879-92.
118. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74.
119. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999; 6:2233-8.
120. Juprelle-Soret M, Wattiaux-De Coninck S, Wattiaux R. Subcellular localization of transglutaminase. Effect of collagen. Biochem J 1988; 50:421-7.
121. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med 2003; 97:643-56.
122. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H. Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 7:737-47.
123. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 1:2929-34.
124. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18:605-17.
125. Ghiringhelli F, Puig PE, Roux S et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202:919-29.
126. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002; 80:477-83.